Asthma and COPD. Health Net Provider Educational Webinar
|
|
- Lindsey Wade
- 6 years ago
- Views:
Transcription
1 Asthma and COPD Health Net Provider Educational Webinar AstraZeneca 2015
2 Disclosures Presenters today are employed by Astra Zeneca and have nothing to disclose. This presentation is free from bias. 2
3 Objectives Today s Learning Objectives Understand the definition and underlying pathophysiology of both COPD and Asthma, as well as differentiate the clinical characteristics between each disease. Understand the role of spirometry to diagnose COPD and asthma and how that translates to patient symptoms. Know the changes that were implemented in the 2017 GOLD Report (Global Initiative for Chronic Obstructive Lung Disease) including changes to diagnosis, assessment and treatment recommendations of patients with COPD. Review the stepwise approach to treatment of patients with Asthma. Understand the emerging characteristics of eosinophilic asthma and the role of eosinophils in severe asthma 3
4 Asthma in Primary Care MAAZAP Approved 09/15 AstraZeneca 2015
5 What Is Asthma? Asthma A chronic inflammatory disorder of the airways in which many cells and factors play a role 1 Inflammation results in 1 Recurrent symptoms Variable airflow obstruction Increase in existing bronchial hyperresponsiveness Asthma patients may have an accelerated decline in lung function and develop airflow limitation that is not fully reversible National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, 2015; 2. GINA. Global Strategy for Asthma Management and Prevention. Updated Accessed August 20, AstraZeneca 2015
6 Every Day Due to Asthma in the US, an Estimated 70,000 absences from school and work 38,000 people experience an asthma attack 5500 ED visits 9 people die 1300 hospitalizations 6 ED = emergency department. Moorman JE et al. Vital Health Stat. 2012;3(35). Accessed August 20, AstraZeneca 2015
7 Key Indicators for a Diagnosis of Asthma Symptoms 1,2 Wheezing, shortness of breath (dyspnea), chest tightness, or cough Characteristics of asthma: >1 symptom Worse at night or in early morning Vary over time and in intensity Triggered by viral infections (colds), exercise, allergen exposure, changes in weather, laughter, or irritants such as car exhaust fumes, smoke, or strong smells Variable Expiratory Airflow Limitation 1 Spirometry is useful to establish a diagnosis of asthma 2 The greater the variations, or the more occasions excess variation is seen, the more confident the diagnosis 1 Confirm that FEV 1 /FVC is reduced (normally > in adults, >0.90 in children) when FEV 1 is low 1 7 FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity. 1. GINA. Global Strategy for Asthma Management and Prevention. Updated Accessed August 20, 2015; 2. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, AstraZeneca 2015
8 Spirometry is Important in Asthma Useful in establishing a diagnosis and guiding management 1 Low FEV 1 is strongly predictive of risk for exacerbations 1,2 Important in assessing control 1 FEV 1 = forced expiratory volume in 1 second National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, Fuhlbrigge AL et al. J Allergy Clin Immunol. 2001;107: AstraZeneca 2015
9 Differentiating Asthma and COPD Asthma COPD Onset 1 Triggers 1 Early in life (often childhood) Allergens Midlife Cigarette smoke, occupational pollutants Symptoms 1 Variable Slowly progressive Clinical features 2,3 Episodic wheeze, chest tightness, cough, dyspnea Chronic dyspnea, cough, sputum, wheeze Inflammatory cells 1 Primarily eosinophils Primarily neutrophils 9 COPD = chronic obstructive pulmonary disease. 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. Accessed August 20, Currie GP, Legge JS. Chapter 3: Diagnosis. Blackwell Publishing; 2007: Dewar M, Curry RW. Am Fam Physician. 2006;73: AstraZeneca 2015
10 Assessing Asthma Control 1,2 Symptom Control Frequency and intensity of daytime and nighttime symptoms Reliever use Activity limitation Work/school days missed Quality of life assessments Future Risk of Adverse Outcomes History of 1 exacerbations in the previous year Lung function (% predicted FEV 1 or FEV 1 /FVC) Inhaler technique and adherence Presence of blood eosinophilia Smoking 10 FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity. 1. GINA. Global Strategy for Asthma Management and Prevention. Updated Accessed August 20, 2015; 2. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, AstraZeneca 2015
11 NAEPP. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Classifying Asthma Severity and Initiating Treatment in Youths 12 Years of Age and Adults Components of Severity Impairment Normal FEV 1 /FVC: 8-19 yr 85% yr 80% yr 75% yr 70% Risk Symptoms Nighttime awakenings SABA use for symptom control (not prevention of EIB) Interference with normal activity Lung function Exacerbations requiring oral systemic corticosteroids Recommended Step for Initiating Treatment Intermittent 2 days/week 2x/month 2 days/week Persistent Mild Moderate Severe >2 days/week but not daily 3-4x/month >2 days/week but not daily and not >1x/day Daily >1x/week but not nightly Daily Throughout the day Often 7x/week Several times per day None Minor limitation Some limitation Extremely limited Normal FEV 1 between exacerbations FEV 1 >80% predicted FEV 1 /FVC normal 0-1/year FEV 1 >80% predicted FEV 1 /FVC normal FEV 1 >60% but <80% predicted FEV 1 /FVC reduced 5% 2/year FEV 1 <60% predicted FEV 1 /FVC reduced >5% Consider severity and interval since last exacerbation Frequency and severity may fluctuate over time for patients of any severity category Relative annual risk of exacerbations may be related to FEV 1 Step 1 Step 2 Step 3 Step 4 In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly EIB = exercise-induced bronchospasm; FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; SABA = short-acting β 2 -adrenergic agonist. 11 Adapted from National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, AstraZeneca 2015
12 NAEPP. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Assessing Asthma Control and Adjusting Therapy in Youths 12 Years of Age and Adults Components of Control Well Controlled Not Well Controlled Very Poorly Controlled Symptoms 2 days/week >2 days/week but not daily Throughout the day Nighttime awakenings 2x/month 1-3x/week 4x/week Interference with normal activity None Some limitation Extremely limited Impairment Risk SABA use for symptom control (not prevention of EIB) FEV 1 or peak flow Validated questionnaires: ATAQ ACQ ACT Exacerbations requiring oral systemic corticosteroids Progressive loss of lung function Treatment-related adverse effects Recommended Action for Treatment 2 days/week >2 days/week Several times per day >80% predicted/ personal best /year 60-80% predicted/ personal best /year Consider severity and interval since last exacerbation Evaluation requires long-term follow-up <60% predicted/ personal best 3-4 N/A 15 Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk Maintain current step Regular follow-ups every 1-6 months to maintain control Consider step down if well controlled for 3 months Step up 1 step and reevaluate in 2-6 weeks For side effects, consider alternative treatment options Consider short course of OCS Step up 1-2 steps and reevaluate in 2 weeks For side effects, consider alternative treatment options 12 ACQ = Asthma Control Questionnaire; ACT = Asthma Control Test; ATAQ = Asthma Therapy Assessment Questionnaire; EIB = exercise-induced bronchospasm; OCS = oral systemic corticosteroids. Adapted from National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, AstraZeneca 2015
13 NAEPP. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Stepwise Approach for Managing Asthma in Patients 12 Years Intermittent Asthma Persistent Asthma: Daily Medication Consult with asthma specialist if Step 4 care or higher is required Consider consultation at Step 3 Step 1 Preferred: SABA PRN Step 2 Preferred: Low-dose ICS (A) Alternative: Cromolyn (A), LTRA (A), Nedocromil (A), or Theophylline (B) Step 3 Preferred: Low-dose ICS + LABA (A) OR Medium-dose ICS (A) Alternative: Low-dose ICS + either LTRA (A), Theophylline (B), or Zileuton (D) Step 4 Preferred: Medium-dose ICS + LABA (B) Alternative: Medium-dose ICS + either LTRA (B), Theophylline (B), or Zileuton (D) Step 5 Preferred: High-dose ICS + LABA (B) AND Consider Omalizumab for Patients Who Have Allergies (B) Each Step: Patient education, environmental control, and management of comorbidities Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma Step 6 Preferred: High-dose ICS + LABA + OCS AND Consider Omalizumab for Patients Who Have Allergies Quick-relief Medication for All Patients SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20- minute intervals as needed. Short course of systemic oral corticosteroids may be needed Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment Step Up If Needed (first, check adherence, environmental control, and comorbid conditions) Assess Control Step Down If Possible (and asthma is well controlled 3 months) 13 EIB = exercise-induced bronchospasm; ICS = inhaled corticosteroid; LABA = long-acting β 2 -adrenergic agonist; LTRA = leukotriene receptor antagonist; OCS = oral systemic corticosteroids; SABA = short-acting β 2 -adrenergic agonist. Adapted from National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. NIH Publication Accessed August 20, AstraZeneca 2015
14 The Role of Eosinophils in Severe/Uncontrolled Asthma MAAZAP Approved 12/16 AstraZeneca 2016 AstraZeneca 2016
15 Asthma Can Be Difficult To Treat The TENOR Study: A prospective, observational, 3-year study of US patients diagnosed with severe or difficult-to-treat asthma 4756 patients of all ages (severity per physician clinical assessment) Mild (3.2%) Moderate (48.4%) Severe (48.4%) 96% Considered Difficult To Treat Need for multiple drugs Frequency of exacerbations Severe exacerbations Inability to avoid triggers Complexity of treatment regimen 15 TENOR=The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; US=United States. Dolan CM, et al. Ann Allergy Asthma Immunol. 2004;92: AstraZeneca 2016
16 Asthma Pathogenesis Allergen Dendritic cell / Macrophage Mast cell IgE Th2 Eosinophil Neutrophil B cell Mucus Plug Nerve activation Epithelial shedding Airway epithelial 16 Mucus hypersecretion Hyperplasia Vasodilation Angiogenesis Fibroblast Airway smooth muscle Plasma leakage Edema Bronchoconstriction IgE=immunogolublin E; Th2=T helper 2 cell. Hypertrophy/hyperplasia Figure adapted from Barnes PJ. Nat Rev Drug Discovery. 2004;3(10): and Gandhi NA et al. Nat Rev Drug Disc. 15;2016: Subepithelial fibrosis Sensory nerve activation Cholinergic reflex AstraZeneca 2016
17 Emerging Characteristics of Eosinophilic Asthma Can be late onset Elevated blood eosinophils! Equal gender distribution No or limited allergies to common allergens Risk of severe exacerbations Normal or moderately elevated IgE Rhinosinusitis with nasal polyps May be aspirin sensitive Low FEV 1 with persistent airflow limitation Dynamic hyperinflation and air trapping 17 FEV 1 =forced expiratory volume in 1 second; IgE=immunoglobulin type E. de Groot JC, et al. ERJ Open Research. 2015;1: AstraZeneca 2016
18 Peripheral Blood Eosinophil Levels Have Been Correlated With Both Asthma Severity and Control Severe Exacerbations Acute Respiratory Events Overall Asthma Control Peripheral Blood Eosinophils cells per µl (n=25,882) cells per µl (n=15,030) cells per µl (n=8659) cells per µl (n=4928) cells per µl (n=2726) cells per µl (n=1631) cells per µl (n=947) cells per µl (n=1019) >1000 cells per µl (n=1019) Adjusted RR a Adjusted RR a Adjusted OR a Severe Exacerbation an asthma-related hospitalization, attendance at an accident and emergency department, or a prescription for acute oral corticosteroids Acute Respiratory Event - defined more broadly as an asthma-related hospital attendance or admission or accident and emergency attendance, prescription for acute oral corticosteroids, or prescription for antibiotics in conjunction with an asthma-related primary care consultation Overall Asthma Control - the absence of any acute respiratory event (as defined above) or asthma-related outpatient department visit with an average daily dose of 200 μg or less salbutamol or 500 μg or less terbutaline 18 a Data from medical records of asthmatics aged years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Patients assigned to 9 eosinophil count categories compared with a reference category of 200 cells per μl or less (n=68,407). Adjusted for age, sex, body-mass index, smoking status, and Charlson comorbidity index score. RR=rate ratio; OR=odds ratio. Price DB, et al. Lancet Respir Med. 2015;3(11): AstraZeneca 2016
19 Increased Eosinophils in Asthma: Major Risk Factor for Exacerbations Historical Analysis of 130,547 Patients with Asthma Age (per year increase) Gender (F vs. M) Overweight vs. normal BMI Obese vs. normal BMI Smoker vs. non-smoker Ex-smoker vs. non-smoker Blood EOS >400/uL vs. 400/uL Anxiety/depression Diabetes (type 1 or 2) Eczema GERD Rhinitis Acetaminophen prescription Odds ratio (95% CI) p-value ( ) < ( ) < ( ) ( ) < ( ) < ( ) ( ) < ( ) ( ) < ( ) ( ) ( ) < ( ) <0.001 Blood eosinophil >400/µL: Single best predictor of multiple exacerbations likelihood of 2 or more exacerbations by 1.5-fold Decreasing likelihood Increasing likelihood of 2+ exacerbations Adapted from Price D et al. J Asthma Allergy 2016;9:1-12 GERD= Gastroesophageal reflux disease ; EOS= Eosinophils; BMI= Body mass index 19 Price D et al. J Asthma Allergy. 2016;9:1-12 AstraZeneca 2016
20 Summary: Increased Eosinophils in Asthma Elevated eosinophils were correlated with: Increased asthma severity 1,2 Worsening lung function 3-5 Exacerbation Risk 6,7 Lung function 3-5 Increased risk of exacerbations 6,7 Increased rates of hospitalizations and ED visits Bousquet J et al. NEJM. 1990;323; Louis R et al. Am J Respir Crit Care Med. 2000; 161; Broekema M et al. Respir Med. 2010; 104: Woodruff PG et al. J Allergy Clin Immunol. 2001;108: McGrath KW et al. Am J Respir Care Med. 2012;185(6): Zeiger RS, et al. J Allergy Clin Immunol Pract. 2014;2: Price D et al. J Asthma Allergy. 2016;9:1-12. AstraZeneca 2016
21 Pathophysiology, Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD) MAAZAP Approved 1/ AstraZeneca
22 Contents Pathophysiology, Diagnosis and Management of COPD presentation 2017 GOLD Report slides AstraZeneca
23 Global Strategy for the Diagnosis, Management, and Prevention of COPD What Is COPD? COPD is... Preventable and treatable Associated with significant concomitant chronic diseases which increase its morbidity and mortality Characterized by persistent respiratory symptoms and airflow limitation that is: due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases 23 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
24 COPD Is a Nationwide Problem In the United States, adults 18 years of age with COPD... are more likely to report being unable to work (24%) than adults who do not have COPD (5%) face activity limitations as a result of health problems (50%) compared with 17% of persons who do not have COPD Quartiles (%) 3.6% 5.0% require the use of special equipment (22%) for health problems compared with 7% of adults without COPD 5.1% 5.9% 6.0% 6.8% 6.9% 10.3% DC = District of Columbia PR = Puerto Rico GU = Guam Centers for Disease Control (CDC), Behavioral Risk Factor Surveillance System, cdc.gov/features/copd-burden. Accessed November 18, Wheaton AG, et al. MMWR. 2015;64(11): AstraZeneca
25 COPD Arises From Damage and Inflammation in the Respiratory Tract Respiratory Anatomy Trachea Bronchi Bronchioles Alveoli 25 Image adapted from AstraZeneca website. Accessed June 2, AstraZeneca
26 Chronic Bronchitis and Airway Inflammation In healthy lungs, the airways are elastic and flexible With chronic bronchitis, airways can become swollen or thicker than normal Chronic bronchitis may cause increased mucus production Airways may become partially obstructed, making it harder to get air out of the lung. The resulting hyperinflation also makes inspiration difficult 26 NIH. National Heart, Lung, and Blood Institute. COPD Learn More Breathe Better. NIH.gov website. Accessed December 17, Images adapted from AstraZeneca website. Accessed December 17, AstraZeneca
27 Emphysema Is Caused by Damage to the Alveoli Walls Healthy alveoli are elastic and capable of springing back to their original size after active inspiration Emphysema involves damage to the walls of the alveoli In emphysema, alveoli lose their elasticity, which impairs natural passive exhalation, resulting in trapping of air and hyperinflation 27 American Thoracic website. Accessed December 17, Images adapted from AstraZeneca website. Accessed December 17, AstraZeneca
28 Global Strategy for the Diagnosis, Management, and Prevention of COPD Key Indicators for a Diagnosis of COPD Symptoms and Past Medical History Dyspnea progressive, worse with exercise, persistent Chronic cough may be intermittent and unproductive, recurrent wheeze Chronic sputum production any pattern of chronic sputum production may indicate COPD Recurrent lower respiratory tract infections History of Risk Factors Host factors (genetic, congenital/developmental) Tobacco smoke Smoke from home cooking/heating fuels Occupational dusts, vapors, fumes gases or chemicals Family History of COPD and/or Childhood Factors AND Airflow Limitation Post-bronchodilator FEV 1 /FVC <0.70* GOLD recommends active casefinding: i.e. Performing spirometry in patients with symptoms and/or risk factors, but not screening spirometry 28 *Required for the diagnosis of COPD. FEV 1 =forced expiratory volume in 1 second; FVC=forced vital capacity. Adapted from Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
29 Global Strategy for the Diagnosis, Management, and Prevention of COPD Use Spirometry to Confirm COPD Diagnosis 1 Post-bronchodilator FEV 1 /FVC <0.70 indicates COPD diagnosis Spirometry Normal Trace Spirometry Obstructive Disease 5 5 Volume, liters FEV 1 = 4 L FVC = 5 L FEV 1 /FVC = 0.8 Volume, liters FEV 1 = 1.8 L FVC = 3.2 L FEV 1 /FVC = Time, Seconds Time, Seconds FEV 1 : Amount of air exhaled in the first second during the FVC maneuver 2 FVC: Total amount of air a person can forcibly exhale after maximum inhalation 2 FEV 1 = forced expiratory volume in one second; FVC = forced vital capacity Adapted from Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, Miller MR,et al. Eur Respir J. 2005;26: AstraZeneca
30 Understanding Lung Volume Measurements in Patients With COPD 1,2 Volume TLC VC Maximum inspiration V T Maximum exhalation IC IC FRC IC FRC RV Normal COPD 30 IC = inspiratory capacity; TLC=total lung capacity; VC=vital capacity; V T =tidal volume; RV=residual volume; FRC=functional residual capacity. 1. Ferguson GT. Proc Am Thorac Soc. 2006;3: Sutherland ER, Cherniack RM. N Engl J Med. 2004;350: AstraZeneca
31 COPD Exacerbations: Risk Factors and Impact Risk factors z Impact Frequent past exacerbations Severity of FEV 1 impairment Chronic bronchial mucus hypersecretion Daily cough and wheeze Increased age Persistent symptoms of chronic bronchitis Comorbid conditions, mainly cardiovascular disease More rapid decline of FEV 1 Increased dyspnea Greater decline in health status Increased mortality 31 Anzueto, A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19:116, AstraZeneca
32 Global Strategy for the Diagnosis, Management, and Prevention of COPD The Refined ABCD Assessment tool (steps 1 and 2) Spirometrically Confirmed Diagnosis Assessment of Airflow Limitation (FEV 1 % predicted) Post-bronchodilator FEV 1 /FVC < 0.7 GOLD 1 80% GOLD 2 50% - 79% GOLD 3 30% - 49% GOLD 4 < 30% 32 Adapted from Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
33 Global Strategy for the Diagnosis, Management, and Prevention of COPD The Refined ABCD Assessment tool (step 3) Exacerbation history Assessment of symptoms/risk of exacerbations 2 or 1 leading to hospital admission C D 0 or 1 (not leading to hospital admission) A B mmrc 0-1 CAT < 10 Symptoms mmrc 2 CAT Adapted from Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
34 Global Strategy for the Diagnosis, Management, and Prevention of COPD Exacerbations GOLD defines an exacerbation as an acute worsening of respiratory symptoms that result in additional therapy Exacerbations are classified as: Mild: Moderate: Severe: Treated with SABDs only Treated with SABDs plus antibiotics and/or oral corticosteroids Patient requires hospitalization or visits the emergency room; + acute respiratory failure 34 SABD = Short-acting bronchodilator. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
35 Global Strategy for the Diagnosis, Management, and Prevention of COPD Goals of COPD Management Reduce Symptoms Reduce Risk Relieve symptoms Improve exercise tolerance Improve health status AND Prevent disease progression Prevent and treat exacerbations Reduce mortality 35 Adapted from Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
36 How Can We Improve COPD Management? COPD remains underdiagnosed 1 Awareness of COPD guidelines suboptimal 2 Spirometry used inconsistently 2 Mortality increasing among women 3 Presentation in the fifth decade of life, 4 though early symptoms may be missed 2 Accurate diagnosis and treatment may lead to better outcomes 5 Appropriate treatment may reduce symptoms and exacerbations, and improve health status 5 Spirometry is key to diagnosis, assessment of severity, and progression of COPD 5 Consideration must also be given to symptom evaluation, exacerbation risk and comorbidities 5 Education represents an opportunity to improve outcomes for COPD patients 2, Mannino DM, et al. MMWR Surveillance Summary. 2002;51: Yawn BP, Wollan PC. Int J COPD. 2008;3: Deaths from chronic obstructive pulmonary disease United States, MMWR Morb Mortal Wkly Rep. 2008;57: American Association for Respiratory Care. Confronting COPD in America: Executive Summary. Accessed December 17, Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
37 Global Strategy for the Diagnosis, Management, and Prevention of COPD Nonpharmacologic Management of COPD Patient Group Essential Recommended Depending on Local Guidelines A Smoking cessation (can include pharmacologic treatment) Physical activity Flu vaccination Pneumococcal vaccination B-D Smoking cessation (can include pharmacologic treatment) Pulmonary rehabilitation Physical activity Flu vaccination Pneumococcal vaccination 37 Adapted from Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, AstraZeneca
38 Global Strategy for the Diagnosis, Management, and Prevention of COPD Pharmacologic Treatment Algorithms Group C Further exacerbation(s) Group A LAMA + LABA LAMA LABA + ICS Group D Consider PDE-4 inhibitor if FEV 1 < 50% pred. and patient has chronic bronchitis Group B Further exacerbation(s) LAMA + LABA + ICS Further exacerbation(s) LAMA LAMA + LABA Consider macrolide (if former smokers) Persistent symptoms / Further exacerbation(s LABA + ICS Continue, stop or try alternative class of bronchodilator Evaluate effect A bronchodilator LAMA + LABA Persistent symptoms long-acting bronchodilator (LABA or LAMA) 38 SABA = short-acting β 2 -agonist; SAMA = short-acting muscarinic antagonist; LABA = long-acting β 2 -agonist; LAMA = long-acting muscarinic antagonist; ICS = inhaled corticosteroid; PDE-4 = phosphodiesterase-4. Adapted from Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Accessed January 6, Preferred treatment 2017 AstraZeneca
39 39 AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism. If you have any comments about this presentation, please contact AstraZeneca at
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation George Anderson, PhD Sr. Medical Science Liaison MA-AZAP ML-4006-US-0212 Approved 11/16 Glob al Strategy for the Diagnosis, Management,
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationAsthma 2015: Establishing and Maintaining Control
Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationAsthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationInhaler Confusion. Today s Speaker Dr. Randall Brown. Director of Asthma Programs 6/7/2016. Dr. Randall Brown March 31, 2016
+ Inhaler Confusion Dr. Randall Brown March 31, 2016 + Today s Speaker Dr. Randall Brown Director of Asthma Programs Center for Managing Chronic Disease University of Michigan 1 ASTHMA ESSENTIALS IN PRIMARY
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCOPD COPD. Update on COPD and Asthma
Update on COPD and Asthma Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco, CA COPD COPD
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationImproving asthma outcomes though education
Improving asthma outcomes though education Segment 1 Clinical Aspects of Asthma and Long term Plan Primary Care and Asthma Most common chronic disease of childhood. Primary care providers are expected
More informationNational Institutes of Health (NIH) NAEPP 2007 Asthma Guideline UPDATE. Susan K. Ross RN, AE-C MDH Asthma Program.
National Institutes of Health (NIH) NAEPP 2007 Asthma Guideline UPDATE Susan K. Ross RN, AE-C MDH Asthma Program 651-201 201-5629 Susan.Ross@health.state.mn.us 1 National Institutes of Health National
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationPediatric Asthma Management
Pediatric Asthma Management APRN Conference February 2016 Cheryl Kerrigan, MSN, CPNP Aimee Tiller RN, AE-C The Plan Definition Pathophysiology review Triggers & Risk Factors Incidence and Prevalence Making
More informationPresented by the California Academy of Family Physicians 2013/California Academy of Family Physicians
Family Medicine and Patient-Centered Asthma Care Presented by the California Academy of Family Physicians Faculty: Hobart Lee, MD Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine
More informationCHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA
CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationWhat is this patient s diagnosis?
Asthma and COPD KANTA VELAMURI, MD ASSOCIATE PROFESSOR OF MEDICINE PULMONARY, CRITICAL CARE AND SLEEP MEDICINE SECTION MICHAEL E. DEBAKEY VA MEDICAL CENTER BAYLOR COLLEGE OF MEDICINE Disclosures None Case
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationRESPIRATORY PHYSIOLOGY Pre-Lab Guide
RESPIRATORY PHYSIOLOGY Pre-Lab Guide NOTE: A very useful Study Guide! This Pre-lab guide takes you through the important concepts that where discussed in the lab videos. There will be some conceptual questions
More informationMedicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air
Medicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air through the airways. As asthma, COPD ( chronic bronchitis
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationThe methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma
The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma Maureen George PhD RN AE-C FAAN Columbia University mg3656@cumc.columbia.edu Faculty Disclosures Maureen George
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationFunction of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)
Function of the Respiratory System Exchange CO2 (on expiration) for O2 (on inspiration) Upper Respiratory Tract Includes: Nose Mouth Pharynx Larynx Function: Warms and humidifies the inspired air Filters
More informationSpirometry Workshop for Primary Care Nurse Practitioners
Spirometry Workshop for Primary Care Nurse Practitioners Catherine Casey S. Jones PhD, RN, AE-C, ANP-C Certified Adult Nurse Practitioner Texas Pulmonary & Critical Care Consultants P.A. and Adjunct Professor
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationNational Institutes of Health (NIH) NAEPP 2007 Asthma Guideline Expert Panel Report (EPR) 3
National Institutes of Health (NIH) NAEPP 2007 Asthma Guideline Expert Panel Report (EPR) 3 Susan K. Ross RN, AE C MDH Asthma Program 651 201 201 5629 Susan.Ross@state.mn.us 1 National Institutes of Health
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationExpert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationDecember 7, 2010 Future Use of Biologics in Allergy and Asthma
December 7, 2010 Future Use of Biologics in Allergy and Asthma Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationTARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS
TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationPeople with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.
COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationHow to distinguish between uncontrolled and severe asthma
How to distinguish between uncontrolled and severe asthma Watch patient using their inhaler. Discuss adherence and barriers to use Compare inhaler technique with a devicespecific checklist, and correct
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationSignificance. Asthma Definition. Focus on Asthma
Focus on Asthma (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Asthma Definition Chronic inflammatory disorder of airways Causes airway hyperresponsiveness
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationPublic Dissemination
1. THE ASTHMA CONDITION 9 18 3 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationI have no perceived conflicts of interest or commercial relationships to disclose.
ASTHMA BASICS Michelle Dickens RN FNP-C AE-C Nurse Practitioner/Certified Asthma Educator Ferrell Duncan Allergy/Asthma/Immunology Coordinator, CoxHealth Asthma Center DISCLOSURES I have no perceived conflicts
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationAsthma. - A chronic inflammatory disorder which causes recurrent episodes of wheezing, breathlessness, cough and chest tightness.
Obstructive diseases Asthma - A chronic inflammatory disorder which causes recurrent episodes of wheezing, breathlessness, cough and chest tightness. - Characterized by Intermittent and reversible (the
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationCurrent Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationAsthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationKnown Allergies: Shellfish. Symptoms: abdominal pain, nausea, diarrhea, or vomiting. congestion, trouble breathing, or wheezing.
CSTAR CASE STUDIES: BLOCK B Asthma or COPD? Setting: Walk in clinic. Dan: I havi g that cough thi g agai HPI: Dan is a 49-year-old male teacher who reports having had episodes of cough with mucus production
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationSCREENING AND PREVENTION
These protocols are designed to implement standard guidelines, based on the best evidence, that provide a consistent clinical experience for AHC II Integrated Clinical Delivery Network patients and allow
More informationASTHMA BEST PRACTICES FOR SCHOOL NURSES. School Nurses November 2015
ASTHMA BEST PRACTICES FOR SCHOOL NURSES School Nurses November 2015 1 BACKGROUND AND CURRENT STATS General definitions and explanations 2 Incidence of Asthma Centers for Disease Control (CDC) - 1 in 12
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More information